We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The National Institutes of Health (NIH) launched two clinical trials yesterday of Eli Lilly’s experimental monoclonal antibody LY-CoV555 for the treatment for COVID-19 patients. Read More
A federal judge in Florida has recommended denying Catalyst Pharmaceuticals’ complaint against the FDA over the agency’s approval of a rare muscle disease drug similar to its own drug Firdapse (amifampridine). Read More
The head of the World Health Organization (WHO) cautioned Monday that no “silver bullet” for the coronavirus may emerge from the flurry of potential vaccines entering phase 3 trials. Read More
Severely ill COVID-19 patients given Relief Therapeutics’ RLF-100 (aviptadil) experienced rapid recovery in just three days, according to the company and its research partner NeuroRx. Read More
Eli Lilly has begun a phase 3 trial of its monoclonal antibody LY-CoV555 for the prevention of COVID-19 in residents and staff at long-term care facilities. Read More